Satellos Bioscience Inc.
MSLE
$11.64
$0.777.08%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 16.92M | 15.32M | 14.45M | 14.31M | 13.00M |
| Gross Profit | -16.92M | -15.32M | -14.45M | -14.31M | -13.00M |
| SG&A Expenses | 7.47M | 6.81M | 6.21M | 5.99M | 6.32M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 24.39M | 22.13M | 20.65M | 20.30M | 19.31M |
| Operating Income | -24.39M | -22.13M | -20.65M | -20.30M | -19.31M |
| Income Before Tax | -21.82M | -22.64M | -21.49M | -20.54M | -20.98M |
| Income Tax Expenses | 114.00K | 95.00K | 63.00K | -- | -- |
| Earnings from Continuing Operations | -21.93 | -22.74 | -21.55 | -20.54 | -20.98 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -21.93M | -22.74M | -21.55M | -20.54M | -20.98M |
| EBIT | -24.39M | -22.13M | -20.65M | -20.30M | -19.31M |
| EBITDA | -24.38M | -22.12M | -20.64M | -20.29M | -19.31M |
| EPS Basic | -1.69 | -1.98 | -2.05 | -2.15 | -2.23 |
| Normalized Basic EPS | -1.05 | -1.04 | -1.09 | -1.15 | -1.20 |
| EPS Diluted | -1.69 | -1.98 | -2.05 | -2.15 | -2.23 |
| Normalized Diluted EPS | -1.05 | -1.04 | -1.09 | -1.15 | -1.20 |
| Average Basic Shares Outstanding | 52.07M | 47.55M | 42.68M | 38.26M | 37.62M |
| Average Diluted Shares Outstanding | 52.07M | 47.55M | 42.68M | 38.26M | 37.62M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |